Expected to benefit 95% of migraine patients with oral CGRP receptor inhibitors approved for extended indications

On May 27, 2021, Biohaven Pharmaceuticals announced that the US FDA has approved its small molecule CGRP receptor inhibitor Nurtec oral disintegrating tablet (rimegepant 75 mg) for extended indications for paroxysmal migraine (number of migraine attacks per month) Less than 15 times) preventive treatment.

The FDA approval is based on a randomized, double-blind, placebo-controlled Phase 3 clinical trial.

Small molecule CGRP receptor inhibitors represent a new class of drugs for the treatment of migraine, and the activity of CGRP is thought to cause migraine pathologically.

Migraine is the disease with the third highest incidence in the world.

Note: The original text has been deleted

Reference materials:

[1] FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment.

https:// and-preventive-treatment-301301304.